Literature DB >> 688737

Alterations in state in apneic pre-term infants receiving theophylline.

J Dietrich, A N Krauss, M Reidenberg, D E Drayer, P A Auld.   

Abstract

The present study is a report on 9 premature infants treated with aminophylline for relief of apnea. With serum theophylline levels of 2 to 10 microgram/ml, all infants experienced significant decrease of apneic episodes in association with increased wakefulness and increased amounts of active (REM) sleep. These effects may occur independently, but it is possible that the alteration of sleep states may be partially responsible for the decrease in apneic episodes in these infants.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 688737     DOI: 10.1002/cpt1978244474

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Metabolic and respiratory effects of theophylline in the preterm infant.

Authors:  V P Carnielli; G Verlato; F Benini; K Rossi; M Cavedagni; M Filippone; E Baraldi; F Zacchello
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-07       Impact factor: 5.747

Review 2.  Drugs in human milk. Clinical pharmacokinetic considerations.

Authors:  H C Atkinson; E J Begg; B A Darlow
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 3.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

Review 4.  Therapeutic monitoring of theophylline. Rationale and current status.

Authors:  C W Bierman; P V Williams
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

5.  Caffeine is a respiratory stimulant without effect on sleep in the short-term in late-preterm infants.

Authors:  Maija Seppä-Moilanen; Sture Andersson; Turkka Kirjavainen
Journal:  Pediatr Res       Date:  2021-10-30       Impact factor: 3.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.